{
    "organizations": [],
    "uuid": "6603fe0ac362e5eade767540216e9b16ae9ebd6b",
    "author": "",
    "url": "https://www.reuters.com/article/brief-pfizer-receives-positive-chmp-opin/brief-pfizer-receives-positive-chmp-opinion-for-two-hematology-medicines-idUSFWN1QD16B",
    "ord_in_thread": 0,
    "title": "BRIEF-Pfizer Receives Positive CHMP Opinion For Two Hematology Medicines",
    "locations": [],
    "highlightText": "",
    "language": "english",
    "persons": [],
    "text": " 15 PM / Updated 9 minutes ago BRIEF-Pfizer Receives Positive CHMP Opinion For Two Hematology Medicines Reuters Staff Feb 23 (Reuters) - Pfizer Inc: * PFIZER RECEIVES POSITIVE CHMP OPINION FOR TWO HEMATOLOGY MEDICINES, MYLOTARG™ AND BOSULIF® * PFIZER INC - CHMP OF EMA HAS ADOPTED POSITIVE OPINIONS RECOMMENDING THAT MYLOTARG, BOSULIF BE GRANTED MARKETING AUTHORIZATIONS IN EU Source text for Eikon: Further company coverage:",
    "published": "2018-02-23T16:12:00.000+02:00",
    "crawled": "2018-02-23T16:33:30.005+02:00",
    "highlightTitle": "",
    "preprocessed_text": [
        "pm",
        "updated",
        "minute",
        "ago",
        "receives",
        "positive",
        "chmp",
        "opinion",
        "two",
        "hematology",
        "medicine",
        "reuters",
        "staff",
        "feb",
        "reuters",
        "pfizer",
        "inc",
        "pfizer",
        "receives",
        "positive",
        "chmp",
        "opinion",
        "two",
        "hematology",
        "medicine",
        "pfizer",
        "inc",
        "chmp",
        "ema",
        "adopted",
        "positive",
        "opinion",
        "recommending",
        "mylotarg",
        "bosulif",
        "granted",
        "marketing",
        "authorization",
        "eu",
        "source",
        "text",
        "eikon",
        "company",
        "coverage"
    ]
}